Michael Lim, MD

Articles by Michael Lim, MD

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors in Glioblastoma

February 9th 2016

Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma.

Latest Updated Articles

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors in Glioblastoma
Published: February 9th 2016 | Updated:

Michael Lim, MD

Articles by Michael Lim, MD

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors in Glioblastoma

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma